GlassScriptPhysician profile
Donna A Wiggins
NPI 1992853394
$2,942.03
in general payments reported to CMS, 2019-2025
38 companies · $469 in 2025
The $469 reported for 2025 was more than what 79% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $312 · 2021: $662 · 2022: $387 · 2023: $463 · 2024: $261 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,148 · Education: $44.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,148.24 |
| Education | $44.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $390.30 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $252.74 | 2019-2025 | |
| Coopersurgical, INC. | $218.55 | 2019-2025 | |
| Amgen INC. | $181.65 | 2019-2024 | Evenity, Prolia |
| Organon LLC | $137.38 | 2021-2025 | Nexplanon |
| Ethicon US, LLC | $123.57 | 2021-2025 | Stratafix, Dermabond, Harmonic |
| Therapeuticsmd, INC. | $121.29 | 2019-2021 | |
| Hologic Sales and Service, LLC | $107.74 | 2020-2025 | Myosure Tissue Removal Device, Acessa Provu System |
| Pfizer INC. | $101.50 | 2021-2025 | |
| Myriad Women'S Health, INC. | $95.67 | 2023 | Myrisk |
| Evofem Biosciences, INC. | $90.67 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $89.51 | 2019-2020 | |
| Exact Sciences Corporation | $88.37 | 2023-2025 | Cologuard Collection Kit |
| Biogen, INC. | $80.90 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $79.85 | 2023-2025 | Veozah |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $77.09 | 2025 | Axonics |
| Millicent US INC | $68.52 | 2024-2025 | Intrarosa, Femring |
| Mayne Pharma Commercial LLC | $66.32 | 2021-2024 | |
| Shield Therapeutics INC | $54.55 | 2023-2025 | Accrufer |
| Ge Healthcare | $49.66 | 2023 | |
| Medicem INC. | $45.48 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $40.65 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $39.49 | 2019 | |
| Becton, Dickinson and Company | $39.49 | 2021 | |
| Agile Therapeutics, INC. | $30.85 | 2021 | |
| Scynexis, INC. | $28.93 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $26.72 | 2025 | |
| Stryker Corporation | $24.80 | 2023 | Universal Neuro 3 |
| Exeltis, USA INC. | $24.49 | 2025 | Slynd |
| Sage Therapeutics, LLC | $24.21 | 2021 | |
| Axonics, INC. | $21.67 | 2024 | Axonics |
| Medtronic, INC. | $21.14 | 2023 | Truclear |
| Avanos Medical | $21.03 | 2021 | |
| Roche Diagnostics Corporation | $17.75 | 2019 | |
| Myriad Genetic Laboratories, INC. | $17.62 | 2021 | |
| Mylan Pharmaceuticals INC. | $14.94 | 2021 | |
| Aspira Women'S Health INC | $14.62 | 2023 | Ova1 |
| Avion Pharmaceuticals | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Wiggins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.